China-based Youjia (Hangzhou) Biomedical Technology Co., Ltd, a leading nucleic acid technology developer, has entered into a strategic cooperation agreement with Yiling Pharmaceutical Co., Ltd (SHE: 002603), marking a significant step into the metabolic diseases field utilizing RNAi technologies. This partnership aims to leverage Youjia’s expertise in nucleic acid drug development to create innovative treatments for metabolic disorders.
Details of the Cooperation Agreement
Under the terms of the agreement, Yiling Pharmaceutical will secure the rights to future development, manufacturing, and commercialization of the resultant drug. Meanwhile, Youjia is set to receive upfront payments, milestone payments, and future sales commissions for their contributions both domestically and internationally.
Youjia Bio’s Nucleic Acid Drug Development Platform
Founded in 2019, Youjia Bio boasts a state-of-the-art nucleic acid drug full-process development platform known as SEQUAD. This platform is designed to accelerate the development and industrialization of nucleic acid drugs and nucleic acid technology products. The collaboration with Yiling Pharmaceutical is expected to further enhance the capabilities of both companies in the field of metabolic disease treatments.-Fineline Info & Tech
Leave a Reply